5 Overhyped Longevity Supplements to Skip in 2026

1. Standard multivitamins

The evidence: 27 years of RCTs show no all-cause mortality benefit. The Physicians' Health Study II followed 14,000+ men for 11 years and found no benefit. Cochrane meta-analyses reach the same conclusion.

Why they persist: the "just in case" heuristic, plus decades of habit. Standard multivitamins deliver underdosed forms of a wide range of nutrients — often the wrong forms (folic acid vs 5-MTHF, cyanocobalamin vs methylcobalamin) at doses too low to matter and combinations that create absorption competition.

The better alternative: targeted supplementation of the specific compounds where you actually have deficits. For most adults, that's D3, omega-3, magnesium, and methylated B-complex — at doses that reach threshold.

2. Ashwagandha and generic "adaptogens" for testosterone

The claim: T-boosting through cortisol modulation. The actual RCT evidence: modest effects, wide confidence intervals, industry-funded trial concentration, and consistent effect degradation in replication.

A 2019 meta-analysis of ashwagandha for testosterone found a mean elevation of ~15-20 ng/dL. Real, but the confidence interval crosses zero in half the trials. Sleep improvement, resistance training, or losing 10 lbs of visceral fat will each drive T harder than any adaptogen.

Where these compounds might have real utility: acute stress management, subjective sleep quality. Not longevity. Not testosterone.

3. Turmeric / curcumin

Curcumin has real anti-inflammatory mechanisms. It also has bioavailability under 1% without piperine or lipid encapsulation, and even with those enhancements, plasma concentrations remain low.

The RCT evidence for curcumin's longevity-relevant endpoints is mixed. Modest joint symptom improvement in osteoarthritis; unclear cognitive or cardiovascular benefit; underwhelming CRP reduction outside high-dose formulations that cost $60+/month.

Opportunity cost: at $60/month, curcumin displaces two months of omega-3 or three months of creatine — both with substantially deeper RCT support.

4. Colostrum, greens powders, and "immunity" blends

The evidence: minimal on longevity-relevant endpoints. Colostrum has some gut-lining RCT signal in athletes with specific GI dysfunction; not a general longevity pick.

Greens powders solve a problem — inadequate vegetable intake — with an inferior solution. The actual longevity signal comes from fiber diversity and polyphenol variety from whole foods, not spray-dried greens at $60+/month.

The better alternative: a $30/month vegetable and berry rotation delivers more targeted fiber, more polyphenols, and more microbiome diversity than any greens powder. If you're not going to eat vegetables, greens powder is a mediocre backup — not a longevity core.

5. Standalone resveratrol (without NMN or NR pairing)

Resveratrol standalone has thin human evidence for the "sirtuin activator" claim that drove the original hype. Most benefits observed in mouse studies did not replicate in humans at achievable doses.

The role resveratrol plays that has some evidence: enhancing NAD+ precursor utilization when paired with NMN or NR. In that pairing, 500mg trans-resveratrol daily has stronger rationale.

Standalone at 500-1000mg: expensive at $30+/month, weak endpoint data, better replaced by getting the trans-resveratrol via the NMN + resveratrol combination products where the pairing is designed in.

The pattern behind these five

Each of the five above shares a common failure mode: marketing surface area disproportionate to evidence base. In each case, the compound sits inside a category with excellent human evidence — and the specific compound is not where the evidence is strongest.

• Multivitamins live in the "nutrient adequacy" category, where targeted D3/omega-3/magnesium beat the multi
• Ashwagandha lives in the "male healthspan" category, where sleep/training/body composition dominate
• Curcumin lives in the "inflammation" category, where omega-3 and Mediterranean diet dominate
• Greens powders live in the "gut/microbiome" category, where dietary diversity dominates
• Standalone resveratrol lives in the "NAD+/sirtuin" category, where NMN or NR dominate

The compound-market failure is not the compound. It's the marketing that makes it look like the best pick in a category where a boring cheaper alternative has 10x the evidence.

Where to redirect the budget

If you're currently spending $150+/month on multivitamin + adaptogens + greens + curcumin, the redirection math is stark:

• The 6-compound beginner stack costs $71-91/month and covers everything the above five claim to
• The remaining $60/month buys creatine + spermidine + a quarterly advanced biomarker panel

Same monthly spend, dramatically more RCT evidence per dollar, and a stack that maps to the actual pathways that predict lifespan.

What's legitimately good (that this article doesn't attack)

To keep the framing honest: many popular longevity supplements are legitimately backed by the evidence. NMN, NR, omega-3, creatine, magnesium, D3, methylated B-complex, spermidine, and — with mechanism-specific rationale — quercetin, PQQ, TMG, and Urolithin A. The category is not overhyped as a whole. Five specific overhyped compounds are.

The full picture — which compounds live inside which pathway, threshold doses, mechanism summaries, and the selection criteria that separate working products from marketed ones — is what the Longevity Vault is built around.